Turn Therapeutics Inc. — Form 8-K Summary
Report date: October 6, 2026. The company furnished this current report to announce an updated investor presentation dated October 6, 2026 (Exhibit 99.1). The presentation itself is not included in the supplied filing text.
Financial and operating information
The 8-K text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It reports no financial results or comparable-period changes.
Outlook, risks, and other disclosures
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the supplied text. The company states that the Item 7.01 information and presentation are furnished, not deemed filed for Exchange Act Section 18 purposes, and not incorporated by reference except by specific reference.
Key facts to verify
- Review Exhibit 99.1 for the presentation’s business, financial, outlook, and risk disclosures; its contents are not available in the supplied text.
- Turn Therapeutics’ common stock trades on Nasdaq under the symbol TTRX.
- The company identifies itself as an emerging growth company.